盐酸安罗替尼联合信迪利单抗注射液治疗对微卫星稳定型结直肠癌患者血管内皮生长因子、转化生长因子-β水平及免疫功能的影响

目的探讨盐酸安罗替尼联合信迪利单抗注射液治疗对微卫星稳定型(MSS)结直肠癌患者血管内皮生长因子(VEGF)、转化生长因子-β(TGF-β)及免疫功能的影响。方法根据治疗方法的不同将经临床标准治疗失败的36例MSS型结直肠癌患者分为单一组(n=16,接受盐酸安罗替尼治疗)和联合组(n=20,接受盐酸安罗替尼联合信迪利单抗治疗)。比较两组患者的临床疗效、不良反应发生情况、VEGF水平、TGF-β水平、T淋巴细胞亚群指标(CD8⁺、CD4⁺、CD4⁺/CD8⁺)及免疫分子含量。结果治疗后,联合组患者的有效率及CD4⁺水平、CD4⁺/CD8⁺均高于单一组患者,血清VEGF、TGF-β水平均低于单一组患者(P﹤0.05)。治疗后,联合组患者肿瘤促进分子CD168、CD133、CD151的含量均明显低于单一组,肿瘤抑制分子CD9、CD63的含量均明显高于单一组患者(P﹤0.01)。结论盐酸安罗替尼联合信迪利单抗对经临床标准治疗失败的MSS型结直肠癌患者具有较好的治疗效果,可降低VEGF、TGF-β水平,抑制肿瘤生长,并提高患者的免疫功能。

Effect of anlotinib hydrochloride combined with sintilimab injection on vascular endothelial growth factor,transforming growth factor-β and immune function of patients with microsatellite stability colorectal cancer

Objective To investigate the effect of anlotinib hydrochloride combined with sintilimab injection on vascular endothelial growth factor(VEGF),transforming growth factor-β(TGF-β)and immune function of patients with microsatellite stability(MSS)colorectal cancer.Method A total of 36 patients with MSS colorectal cancer failed to respond to standard clinical treatment divided into single-agent group(receiving anlotinib hydrochloride treatment)and combination group(receiving anlotinib hydrochloride combined with sintilimab treatment)according to different treatment regimens.The clinical efficacy,adverse reactions,levels of VEGF,levels of TGF-β,T lymphocyte subgroup indicators(CD8⁺,CD4⁺,CD4⁺/CD8⁺)and immune molecular content were compared between the two groups of patients.Result After treatment,the combination group’s response rate,the serum levels of CD4⁺and CD4⁺/CD8⁺were higher than that of the single-agent group(P<0.05).After treatment,the serum levels of VEGF and TGF-βin the combined group were lower than those in the single-agent group(P<0.05).After treatment,the levels of tumor-promoting molecules CD168,CD133 and CD151 in the combination group were significantly lower than those in the single-agent group,the levels of tumorsuppressing molecules CD9 and CD63 were significantly higher than those in the single-agent group(P<0.01).Conclusion Anlotinib hydrochloride combined with sintilimab has a good therapeutic effect on patients with MSS colorectal cancer who have failed to respond to the standard clinical treatment.The combined regimen could down-regulate the levels of VEGF and TGF-β,inhibit tumor growth,and improve patients’immune function.